Diatide NeoTect Future Indications Will Be Evaluated Off-Label
This article was originally published in The Gray Sheet
Executive Summary
Diatide says that a $2 mil. milestone payment from marketing partner Nycomed Amersham triggered by FDA's Aug. 3 approval of NeoTect will be used in part to bolster its own marketing efforts for the lung cancer imaging agent.
You may also be interested in...
Schering Entering Radiopharmaceuticals Market Via $128 Mil. Diatide Deal
Schering AG is looking to accelerate its expansion into the worldwide radiopharmaceuticals market through the acquisition of Diatide. The $128 mil. cash deal was announced Sept. 20.
Schering Entering Radiopharmaceuticals Market Via $128 Mil. Diatide Deal
Schering AG is looking to accelerate its expansion into the worldwide radiopharmaceuticals market through the acquisition of Diatide. The $128 mil. cash deal was announced Sept. 20.
Nycomed Amersham's Sonazoid
New drug application is submitted for the ultrasound contrast agent. Based on results with 1,300 patients in Europe and the U.S., the NDA includes clinical data "demonstrating echocardiographic improvement in endocardial border delineation and left ventricular opacification following administration" of the drug, the firm says Aug. 6. On Aug. 3, FDA approved Diatide's NDA for the lung cancer detection agent NeoTect, which Nycomed Amersham is co-promoting in the U.S. (1see related story, p. 10)